Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds
US2016287540A1
Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds
EP3033150A1
Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types
US2014336150A1
Administration of karenitecin for the treatment of platinum and/or taxane chemotherapy-resistant or -refractory advanced ovarian cancer
WO2014078168A1
Methods for the total chemical synthesis of enantiomerically-pure 7-(2'-trimethylsilyl) ethyl camptothecin
WO2014039787A2
Germanium-containing camptothecin analogues
JP2010184936A
Method for treating radiation-exposed patient
US2009111735A1
Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
EP2249826A1
Compositions and methods of use of compounds to increase cancer patient survival time
US2009232906A1
Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
AU2008352597A1
Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
WO2009113984A1
Chemoprotective methods and compositions
US2008161414A1
Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
US2008194680A1
Platinum analogs with bis-nitrile-containing ligands
US2009099224A1
C7-substituted camptothecin analogs
CA2700905A1
C7-substituted camptothecin analogs
EP2197279A1
C10-substituted camptothecin analogs
US2009099166A1
C10-substituted camptothecin analogs
US2008261919A1
Camptothecin-analog with a novel, “flipped” lactone-stable, E-ring and methods for making and using same
WO2007109184A2
Anti-cancer activity augmentation compounds and formulations and methods of use thereof
